1-20 of 212
Nyla A. Heerema
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL

CME Clinical Trials & Observations
Jennifer A. Woyach, Gabriela Perez Burbano, Amy S. Ruppert, Cecelia Miller, Nyla A. Heerema, Weiqiang Zhao, Anna Wall, Wei Ding, Nancy L. Bartlett, Danielle M. Brander, Paul M. Barr, Kerry A. Rogers, Sameer A. Parikh, Deborah M. Stephens, Jennifer R. Brown, Gerard Lozanski, James Blachly, Sreenivasa Nattam, Richard A. Larson, Harry Erba, Mark Litzow, Selina Luger, Carolyn Owen, Charles Kuzma, Jeremy S. Abramson, Richard F. Little, Shira Dinner, Richard M. Stone, Geoffrey Uy, Wendy Stock, Sumithra J. Mandrekar, John C. Byrd
Journal: Blood
Blood (2024) 143 (16): 1616–1627.
https://doi.org/10.1182/blood.2023021959
Published: 2024
Includes: Supplemental data
Journal Articles

Feasibility and Outcome of Post-Induction Therapy Incorporating Dasatinib for Patients with Newly Diagnosed ABL-Class Fusion B-Lymphoblastic Leukemia (ABL-class Fusion B-ALL): Children's Oncology Group AALL1131

Wanda L. Salzer, Michael J. Burke, Meenakshi Devidas, Zhiguo (Bruce) Chen, Michael J. Borowitz, Andrew J Carroll, I-Ming L. Chen, Julie M. Gastier-Foster, Richard C. Harvey, Nyla A. Heerema, Charles G. Mullighan, Karen R. Rabin, Shalini C Reshmi, Cheryl L. Willman, Brent L. Wood, Naomi J. Winick, William L. Carroll, Elizabeth A. Raetz, Mignon L. Loh, Stephen P. Hunger
Journal: Blood
Blood (2023) 142 (Supplement 1): 961.
https://doi.org/10.1182/blood-2023-190495
Published: 2023
Journal Articles

Patients with Down Syndrome and High-Risk B-Acute Lymphoblastic Leukemia Demonstrate Improved Outcomes on a Modified Chemotherapy Regimen: A Report from Children's Oncology Group Study AALL1131

Vilmarie Rodriguez, Meenakshi Devidas, Zhiguo (Bruce) Chen, Andrew J Carroll, Nyla A. Heerema, Michael J. Borowitz, Brent L. Wood, William L. Carroll, Naomi J Winick, Elizabeth A. Raetz, Mignon L. Loh, Michael J. Burke, Wanda L. Salzer, Stephen P. Hunger, Karen R. Rabin
Journal: Blood
Blood (2023) 142 (Supplement 1): 824.
https://doi.org/10.1182/blood-2023-185368
Published: 2023
Journal Articles

Genomic Characterization of Newly Diagnosed Acute Myeloid Leukemia in Patients Age 60 Years and Older; A Report from the Beat AML Master Trial

Fieke W Hoff, Ying Huang, Rina Li Welkie, Ronan T. Swords, Elie Traer, Eytan M. Stein, Tara L Lin, Prapti A. Patel, Robert H. Collins, Maria R. Baer, Vu H. Duong, William Blum, Martha Arellano, Wendy Stock, Olatoyosi Odenike, Robert L. Redner, Tibor J. Kovacsovics, Michael W. Deininger, Joshua F. Zeidner, Rebecca Olin, Catherine C. Smith, James M. Foran, Gary J. Schiller, Emily K Curran, Kristin L Koenig, Nyla A. Heerema, Timothy Chen, Molly Martycz, Mona Stefanos, Sonja Gullen Marcus, Leonard Rosenberg, Brian J. Druker, Ross L Levine, Amy Burd, Ashley Owen Yocum, Uma M. Borate, Alice Mims, John C. Byrd, Yazan F. Madanat
Journal: Blood
Blood (2023) 142 (Supplement 1): 4296.
https://doi.org/10.1182/blood-2023-187044
Published: 2023
Journal Articles

A Randomized Phase 2 Trial of 28-Day (Arm A) Versus 14-Day (Arm B) Schedule of Venetoclax + Azacitidine in Newly Diagnosed Acute Myeloid Leukemia Patients ≥ 60 Years

Uma M. Borate, Ying Huang, Mary F. Johnson, Joshua F. Zeidner, Ronan T. Swords, Kristin L Koenig, Eytan M. Stein, Maria R. Baer, Wendy Stock, Yazan F. Madanat, Rebecca Olin, William Blum, Gary J. Schiller, Tara L Lin, Robert L. Redner, Emily K Curran, Nyla A. Heerema, Molly Martycz, Leonard Rosenberg, Sonja Gullen Marcus, Timothy Chen, Mona Stefanos, Ross L Levine, Brian J. Druker, Ashley Owen Yocum, Amy Burd, Alice Mims, John C. Byrd
Journal: Blood
Blood (2023) 142 (Supplement 1): 1535.
https://doi.org/10.1182/blood-2023-187383
Published: 2023
Journal Articles

Risk-Adjusted Therapies Yield Equivalent Outcomes for Adolescents and Young Adults (AYAs) Treated for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) on Children's Oncology Group (COG) Studies AALL0434 and AALL1231

Susan I. Colace, Meenakshi Devidas, Zhiguo (Bruce) Chen, Robert J. Hayashi, Brent L. Wood, Natia Esiashvili, Samir Patel, Andrew J Carroll, Nyla A. Heerema, Barbara Asselin, Karen R. Rabin, Patrick A. Zweidler-McKay, Elizabeth A. Raetz, Mignon L. Loh, Naomi J. Winick, William L. Carroll, David T. Teachey, Stuart S. Winter, Kimberly P. Dunsmore
Journal: Blood
Blood (2023) 142 (Supplement 1): 517.
https://doi.org/10.1182/blood-2023-190141
Published: 2023
Journal Articles

Influence of Pre-Treatment Features and Therapy Choice By Physicians on Overall Survival in Older Adults with Acute Myeloid Leukemia: A Report from the Beat AML Master Trial

Uma M. Borate, Ying Huang, Rina Li Welkie, Ronan T. Swords, Elie Traer, Eytan M. Stein, Tara L Lin, Yazan F. Madanat, Prapti A. Patel, Robert H. Collins, Maria R. Baer, Vu H. Duong, William Blum, Martha Arellano, Wendy Stock, Olatoyosi Odenike, Robert L. Redner, Tibor J. Kovacsovics, Michael W. Deininger, Joshua F. Zeidner, Rebecca Olin, Catherine C. Smith, James M. Foran, Gary J. Schiller, Emily K Curran, Kristin L Koenig, Nyla A. Heerema, Timothy Chen, Molly Martycz, Mona Stefanos, Sonja Gullen Marcus, Leonard Rosenberg, Brian J. Druker, Ross L Levine, Amy Burd, Ashley Owen Yocum, Alice Mims, John C. Byrd
Journal: Blood
Blood (2023) 142 (Supplement 1): 4332.
https://doi.org/10.1182/blood-2023-181886
Published: 2023
Journal Articles

Beat AML S8 Group 2: Gilteritinib (GILT) in Combination with Decitabine (DEC) and Venetoclax (VEN) in Untreated FLT3 Mutated Acute Myeloid Leukemia (AML) Patients Age ≥60 with High and Low Variant Allele Frequency (VAF)

Qiuying (Selina) Liu, Rina Li Welkie, Ying Huang, Ronan T. Swords, Tara L Lin, Kristin L Koenig, Yazan F. Madanat, Prapti A. Patel, Robert H. Collins, William Blum, Martha Arellano, Maria R. Baer, Wendy Stock, Tibor J. Kovacsovics, Rebecca Olin, Emily K Curran, Eytan M. Stein, Gary J. Schiller, Joshua F. Zeidner, Robert L. Redner, Nyla A. Heerema, Molly Martycz, Leonard Rosenberg, Sonja Gullen Marcus, Timothy Chen, Mona Stefanos, Ross L Levine, Brian J. Druker, Ashley Owen Yocum, Amy Burd, Alice Mims, Uma M. Borate, John C. Byrd, Elie Traer
Journal: Blood
Blood (2023) 142 (Supplement 1): 5933.
https://doi.org/10.1182/blood-2023-179609
Published: 2023
Journal Articles

Genomic landscape of Down syndrome–associated acute lymphoblastic leukemia

Zhenhua Li, Ti-Cheng Chang, Jacob J. Junco, Meenakshi Devidas, Yizhen Li, Wenjian Yang, Xin Huang, Dale J. Hedges, Zhongshan Cheng, Mary Shago, Andrew J. Carroll, Nyla A. Heerema, Julie Gastier-Foster, Brent L. Wood, Michael J. Borowitz, Lauren Sanclemente, Elizabeth A. Raetz, Stephen P. Hunger, Eleanor Feingold, Tracie C. Rosser, Stephanie L. Sherman, Mignon L. Loh, Charles G. Mullighan, Jiyang Yu, Gang Wu, Philip J. Lupo, Karen R. Rabin, Jun J. Yang
Journal: Blood
Blood (2023) 142 (2): 172–184.
https://doi.org/10.1182/blood.2023019765
Published: 2023
Includes: Supplemental data
Journal Articles

Central nervous system status is prognostic in T-cell acute lymphoblastic leukemia: a Children’s Oncology Group report

Clinical Trials & Observations
Nathan P. Gossai, Meenakshi Devidas, Zhiguo Chen, Brent L. Wood, Patrick A. Zweidler-McKay, Karen R. Rabin, Mignon L. Loh, Elizabeth A. Raetz, Naomi J. Winick, Michael J. Burke, Andrew J. Carroll, Natia Esiashvili, Nyla A. Heerema, William L. Carroll, Stephen P. Hunger, Kimberly P. Dunsmore, Stuart S. Winter, David T. Teachey
Journal: Blood
Blood (2023) 141 (15): 1802–1811.
https://doi.org/10.1182/blood.2022018653
Published: 2023
Includes: Supplemental data
Journal Articles

A Phase 1b Dose Escalation and Expansion Study of SNDX-5613, Azacitidine (AZA) and Venetoclax (VEN) in Newly Diagnosed, Patients ≥ 60 Years with Untreated NPM1 -Mutated/ FLT3 -Wild Type AML or KMT2A -Rearranged Acute Myeloid Leukemia (AML)

Joshua F. Zeidner, Matthew C. Foster, Mary Johnson, Ying Huang, Ronan T. Swords, Eytan Stein, James M. Foran, Maria R. Baer, Wendy Stock, Yazan F. Madanat, Tibor Kovacsovics, Rebecca L. Olin, William G. Blum, Gary J. Schiller, Tara L. Lin, Robert L. Redner, Zeina Al-Mansour, Emily K Curran, Nyla A. Heerema, Molly Martycz, Leonard Rosenberg, Sonja Marcus, Ashley O. Yocum, Timothy Chen, Mona Stefanos, Franchesca Druggan, Amy Burd, Ross L. Levine, Brian J. Druker, Uma Borate, John C. Byrd, Alice S. Mims
Journal: Blood
Blood (2022) 140 (Supplement 1): 9070–9073.
https://doi.org/10.1182/blood-2022-166715
Published: 2022
Journal Articles

FISH Analysis of CDKN2A/B Deletion in Chronic Lymphocytic Leukemia

Samantha M Teierle, Ying Huang, Adam S Kittai, Seema A. Bhat, Michael R. Grever, Kerry A. Rogers, Weiqiang Zhao, Daniel Jones, John C. Byrd, Matthew R Avenarius, Nyla A. Heerema, Jennifer A. Woyach, Cecelia Miller
Journal: Blood
Blood (2022) 140 (Supplement 1): 7016–7017.
https://doi.org/10.1182/blood-2022-163753
Published: 2022
Journal Articles

Entospletinib (ENTO) in Combination with Cytarabine (Ara-C) and Daunorubicin (DNR) in Newly Diagnosed (ND) Adult Patients with NPM1 -Mutated and FLT3 -ITD Wild-Type Acute Myeloid Leukemia (AML) Is Associated with Good Response and Survival: A Phase 2 Sub-Study of the Beat AML Master Trial

Uma Borate, Rui Li, Ying Huang, Ronan T. Swords, Elie Traer, Eytan Stein, James M. Foran, Maria R. Baer, Vu H. Duong, Wendy Stock, Olatoyosi Odenike, Prapti Patel, Robert H. Collins, Yazan F. Madanat, Tibor Kovacsovics, Michael W. Deininger, Catherine Smith, Rebecca L. Olin, Martha L. Arellano, William G. Blum, Gary J. Schiller, Tara L. Lin, Matthew C. Foster, Michael M. Boyiadzis, Robert L. Redner, Zeina Al-Mansour, Emily K Curran, Nyla A. Heerema, Theophilus J Gana, Molly Martycz, Leonard Rosenberg, Sonja Marcus, Ashley O. Yocum, Timothy Chen, Mona Stefanos, Franchesca Druggan, Amy Burd, Ross L. Levine, Brian J. Druker, John C. Byrd, Alice S. Mims
Journal: Blood
Blood (2022) 140 (Supplement 1): 6200–6203.
https://doi.org/10.1182/blood-2022-167316
Published: 2022
Journal Articles

Prognostic Importance of Cytogenetic Subgroups in Relapse Risk Stratification in Children and Young Adults with First Relapsed B-ALL: A Children's Oncology Group Study AALL1331

Teena Bhatla, Laura Hogan, Xinxin Xu, Lingyun Ji, Andrew J. Carroll, Nyla A. Heerema, Mary Shago, Lia Gore, James A. Whitlock, Stephen P. Hunger, Mignon L. Loh, Patrick A. Brown
Journal: Blood
Blood (2022) 140 (Supplement 1): 3476–3477.
https://doi.org/10.1182/blood-2022-166523
Published: 2022
Journal Articles

A Risk-Adapted Study to Assess the Efficacy of Enasidenib and Subsequent Response-Driven Addition of Azacitidine for Newly Diagnosed IDH2 -Mutant AML Patients: 3-Year Follow-up

Eytan Stein, Sheng F Cai, Ying Huang, Andrew Dunbar, Maria R. Baer, Wendy Stock, Tibor Kovacsovics, William G. Blum, Gary J. Schiller, Rebecca L. Olin, James M. Foran, Mark R. Litzow, Tara L. Lin, Prapti A. Patel, Matthew C. Foster, Michael M. Boyiadzis, Robert H. Collins, Jordan Chervin, Abigail B. Shoben, Jo-Anne Vergilio, Nyla A. Heerema, Leonard Rosenberg, Timothy Chen, Ashley O. Yocum, Franchesca Druggan, Sonja Marcus, Mona Stefanos, Molly Martycz, Brian J. Druker, Alice S. Mims, Uma Borate, Amy Burd, John C. Byrd, Ross L. Levine
Journal: Blood
Blood (2022) 140 (Supplement 1): 2016–2019.
https://doi.org/10.1182/blood-2022-166850
Published: 2022
Journal Articles

A Pilot Study of Azacitidine As Epigenetic Priming for Chemotherapy in Infants Less Than 1 Year of Age with KMT2A -Rearranged Acute Lymphoblastic Leukemia (ALL); Results from the Children's Oncology Group (COG) Trial AALL15P1

Erin Guest, John Kairalla, Meenakshi Devidas, Emily Hibbitts, Andrew J. Carroll, Nyla A. Heerema, Holly Kubaney, Amanda August, Melinda Pauly, Daniel Wechsler, Rodney R. Miles, Joel M. Reid, Cynthia Kihei, Lia Gore, Elizabeth A. Raetz, Stephen P. Hunger, Mignon L. Loh, Patrick A. Brown
Journal: Blood
Blood (2022) 140 (Supplement 1): 3256–3257.
https://doi.org/10.1182/blood-2022-167765
Published: 2022
Journal Articles

The impact of increasing karyotypic complexity and evolution on survival in patients with CLL treated with ibrutinib

Clinical Trials & Observations
Adam S. Kittai, Cecelia Miller, Daniel Goldstein, Ying Huang, Lynne V. Abruzzo, Kyle Beckwith, Seema A. Bhat, David A. Bond, Michael R. Grever, Nyla A. Heerema, Kerry A. Rogers, Amy S. Ruppert, John C. Byrd, Jennifer A. Woyach
Journal: Blood
Blood (2021) 138 (23): 2372–2382.
https://doi.org/10.1182/blood.2020010536
Published: 2021
Includes: Supplemental data
Journal Articles

Ivosidenib (IVO) in Combination with Azacitidine (AZA) in Newly Diagnosed (ND) Older Patients with IDH1 R132-Mutated Acute Myeloid Leukemia (AML) Induces High Response Rates: A Phase 2 Sub-Study of the Beat AML Master Trial

Prapti Patel, Amy S. Ruppert, Uma Borate, Eytan M. Stein, Maria R. Baer, Wendy Stock, Tibor Kovacsovics, William Blum, Martha L. Arellano, Gary J. Schiller, Rebecca L. Olin, James M. Foran, Mark R. Litzow, Tara L. Lin, Matthew C. Foster, Robert L. Redner, Zeina Al-Mansour, Christopher R. Cogle, Michael M. Boyiadzis, Ronan Swords, Robert H. Collins, Jo-Anne Vergilio, Nyla A. Heerema, Leonard Rosenberg, Ashley Owen Yocum, Sonja Marcus, Timothy Chen, Franchesca Druggan, Mona Stefanos, Theophilus J Gana, Abigail B. Shoben, Brian J. Druker, Amy Burd, John C. Byrd, Ross L. Levine, Alice S. Mims
Journal: Blood
Blood (2021) 138 (Supplement 1): 875.
https://doi.org/10.1182/blood-2021-149115
Published: 2021
Journal Articles

Comparison of Current and Enhanced Risk Stratification of 21,199 Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia Using Objective Risk Categorization Criteria: A Children's Oncology Group Report

Natalie Delrocco, Mignon L. Loh, Michael Borowitz, Karen R Rabin, Patrick A Zweidler-McKay, Kelly W Maloney, Leonard A. Mattano, Eric C Larsen, Anne L Angiolillo, Reuven J Schore, Michael J. Burke, Wanda L Salzer, Brent L. Wood, Andrew J Carroll, Nyla A. Heerema, Shalini C Reshmi, Julie M Gastier-Foster, Richard C Harvey, I-Ming L Chen, Kathryn G Roberts, Charles G. Mullighan, Cheryl L Willman, Naomi J Winick, William L. Carroll, Stephen P. Hunger, Elizabeth A. Raetz, Meenakshi Devidas, John Kairalla
Journal: Blood
Blood (2021) 138 (Supplement 1): 2382.
https://doi.org/10.1182/blood-2021-148593
Published: 2021
Journal Articles

Gilteritinib (GILT) Monotherapy with Addition of Decitabine (DEC) in Non-Responders in Older Newly Diagnosed (ND) FLT3 Mutated Acute Myeloid Leukemia (AML) Patients Having High and Low Variant Allele Frequency (VAF): A Phase 2/1b Sub-Study of the Beat AML Master Trial

Elie Traer, Ying Huang, Alice S. Mims, Eytan M. Stein, Maria R. Baer, Wendy Stock, Tibor Kovacsovics, William Blum, Martha L. Arellano, Gary J. Schiller, Rebecca L. Olin, James M. Foran, Mark R. Litzow, Tara L. Lin, Prapti Patel, Matthew C. Foster, Robert L. Redner, Zeina Al-Mansour, Christopher R. Cogle, Michael M. Boyiadzis, Ronan Swords, Robert H. Collins, Jo-Anne Vergilio, Nyla A. Heerema, Leonard Rosenberg, Ashley O. Yocum, Sonja Marcus, Timothy Chen, Franchesca Druggan, Mona Stefanos, Theophilus J Gana, Abigail B. Shoben, Brian J. Druker, Amy Burd, John C. Byrd, Ross L. Levine, Uma Borate
Journal: Blood
Blood (2021) 138 (Supplement 1): 1277.
https://doi.org/10.1182/blood-2021-148207
Published: 2021